[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-404491-105":59,"doc-detail-404491-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","new-opportunities-implementing-long-acting-prep-in-clinical-practice-challenges-and-implementation-science","New Opportunities: Implementing Long-Acting PrEP in Clinical Practice - Challenges and Implementation Science","","Conference style overview of implementing long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis in routine clinical practice. Summarizes evidence from HPTN 083/084 on superiority versus oral TDF/FTC controls and tolerability, then details FDA approval, slow uptake, and cost drivers in the US compared with branded and generic options. Describes global CAB-LA rollout status, ongoing and planned implementation science studies (including key populations and delivery approaches), and outlines patient access barriers and savings programs, including eligibility rules and coverage mechanics.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/new-opportunities-implementing-long-acting-prep-in-clinical-practice-challenges-and-implementation-science/404491/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/new-opportunities-implementing-long-acting-prep-in-clinical-practice-challenges-and-implementation-science/404491.png","ImageObject",300,407,{"name":92,"@type":93},"A glass of water","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-27",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What evidence supports injectable CAB-LA as long-acting PrEP?","Question",{"text":113,"@type":114},"HPTN 083/084 showed CAB-LA superiority versus the TDF/FTC control and it was well tolerated despite injection site reactions.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What are the main challenges to implementing LA CAB in clinical practice?",{"text":118,"@type":114},"Key challenges include slow uptake, high and variable costs, insurance and workflow barriers, staff limitations for navigation and paperwork, missed injections, and limited patient demand.",{"name":120,"@type":111,"acceptedAnswer":121},"Which implementation science studies are underway or planned, and what populations do they target?",{"text":122,"@type":114},"Planned and ongoing studies include PILLAR, EBONI, Aurora, INNOVATE, plus multiple studies in South Africa and other countries, targeting MSM, transgender women, cisgender women, and people who inject drugs, and evaluating delivery support such as digital health and non-gluteal injection sites.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},404491,1791093262,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},962090760832,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","New Opportunities: Implementing Long-Acting PrEP in Clinical Practice  \nKenneth H. Mayer, MD  \nDisclosures  \n• Unrestricted institutional research grants: Gilead Sciences, Merck Inc, ViiV  \n• Scientific Advisory Board: Gilead, Merck  \n• NIH funding to study antiretrovirals for prevention  \nInjectable Cabotegravir: Game Changer?  \n-HPTN 083/084 showed superiority of CAB-LA vs.TDF/FTC control  \n-CAB-LA was well tolerated despite injection site reactions  \nChallenges to LA CAB Implementation  \n• FDA approved 12/20/21  \n• Uptake has been slow  \n• Cost in US: ≈$26,000/yr.  \n• DescovyTM $23,748/yr.  \n• Generic Truvada $588/yr.  \n• Cost  \n• Insurance  \n• Workflow  \n• Missed Injections  \n• Pt. preference  \nGlobal CAB LA Roll Out  \n• Approved: Australia, Botswana. Malawi, South Africa, USA  \n• Recent EMA review→expect approval soon  \n• Pending approval: Brazil, Kenya, Malaysia, Peru, Philippines, Uganda, Ukraine, Vietnam, Zambia, Zimbabwe  \n• To be filed soon: Argentina, Colombia, Coted’Ivoire, Mozambique, Nigeria, Rwanda, Tanzania  \nSource: AVAC  \nCAB-LA Implementation Science (IS)  \nStudies Underway or Planned ([www.prepwatch.org](www.prepwatch.org) )  \n• PILLAR (US): 220 cis and transgender MSM, inc. telehealth support • EBONI (US): 250 Black cisgender women  \n• Aurora (US): Digital health and behavioral economics  \n• INNOVATE (US): PWID  \n• IS studies underway in Kenya, Uganda, Zimbabwe, Lesotho  \n• Multiple studies underway in South Africa, including Thetha Nami Ngithethe Nave (“Let’s talk) enrolling 26,000 pts. Step wedge design with peer navigation for youth  \n• IS studies focusing on key pops, mainly MSM/TGW in Brazil, Burkina Faso, Cote d’Ivoire, Mali, Australia, France  \n• Studies underway to evaluate non-gluteal injection sites  \n• Studies underway to evaluate mHealth support for TGW, women who inject drugs  \n| What have been the biggest challenges in making CAB LA available to your patients? | 10\u003Cbr>experts |\n| --- | --- |\n| Lack of staff to help navigate patients to appropriate resources | 10 |\n| Insurance coverage | 9 |\n| Lack of staff to complete paperwork | 6 |\n| Lack of staff or time to administer injections* | 4 |\n| Lack of patient demand | 0 |\n\n*”process takes weeks to complete” “frequent change insurance plans”“staff time also needed to deal with missed injections, etc” frequency of viral loads  \nPatient Savings Programs (ViiV)  \nPatient Assistance Program  \n• Live in one of the 50 states, DC, or Puerto Rico  \n• Household income \u003C/= to 500% of the Federal Poverty Level  \n• Not eligible for Medicaid, and either have no rx. coverage or:  \n• Have a Medicare Part B, D, or Advantage Plan, spent at least >/= $600 on out-of-pocket rx. expenses during the current calendar year, or  \n• Have a private insurance plan limited to generic-only coverage  \nInjection fee not covered  \n| Patient Savings Program |  |\n| --- | --- |\n| • Patients with commercial Insurance\u003Cbr>• Can receive up to: $7,850/yr beyond what insurance will cover\u003Cbr>• Patients will receive a virtual debit card they can use to pay their bill\u003Cbr>• Gets reviewed periodically, and needs new paperwork if insurance changes\u003Cbr>• Several states will cover additional gaps with PrEPDAP programs\u003Cbr>[https://www.viivconnect.com/for](https://www.viivconnect.com/for)providers/financial-support/ |  |","cbCaivQpw3K8Y4uO","https://ap.wps.com/l/cbCaivQpw3K8Y4uO","pdf",1405540,17,"English","# Injectable Cabotegravir (CAB-LA): Evidence and status\n## HPTN 083/084 findings\n## Challenges to LA CAB implementation\n## Global CAB LA roll out\n# CAB-LA Implementation Science (IS)\n## Studies underway or planned\n## Key populations and delivery innovations\n# Patient access: barriers and savings programs\n## Biggest challenges reported by experts\n## Patient Savings Programs (ViiV) eligibility and coverage","[{\"question\":\"What evidence supports injectable CAB-LA as long-acting PrEP?\",\"answer\":\"HPTN 083/084 showed CAB-LA superiority versus the TDF/FTC control and it was well tolerated despite injection site reactions.\"},{\"question\":\"What are the main challenges to implementing LA CAB in clinical practice?\",\"answer\":\"Key challenges include slow uptake, high and variable costs, insurance and workflow barriers, staff limitations for navigation and paperwork, missed injections, and limited patient demand.\"},{\"question\":\"Which implementation science studies are underway or planned, and what populations do they target?\",\"answer\":\"Planned and ongoing studies include PILLAR, EBONI, Aurora, INNOVATE, plus multiple studies in South Africa and other countries, targeting MSM, transgender women, cisgender women, and people who inject drugs, and evaluating delivery support such as digital health and non-gluteal injection sites.\"}]","New Opportunities: Implementing Long-Acting PrEP in Clinical Practice - Challenges and Implementation Science | PDF",1790548268,43]